Gillatt DA - Search Results

1

The feasibility of Miltuximab®-IRDye700DX-mediated photoimmunotherapy of solid tumors.

Polikarpov DM, Campbell DH, Lund ME, Lu Y, Lu Y, Wu J, Walsh BJ, Zvyagin AV, Gillatt DA. Polikarpov DM, et al. Among authors: gillatt da. Photodiagnosis Photodyn Ther. 2020 Dec;32:102064. doi: 10.1016/j.pdpdt.2020.102064. Epub 2020 Oct 15. Photodiagnosis Photodyn Ther. 2020. PMID: 33069874

2

Near-Infrared Molecular Imaging of Glioblastoma by Miltuximab^®-IRDye800CW as a Potential Tool for Fluorescence-Guided Surgery.

Polikarpov DM, Campbell DH, McRobb LS, Wu J, Lund ME, Lu Y, Deyev SM, Davidson AS, Walsh BJ, Zvyagin AV, Gillatt DA. Polikarpov DM, et al. Among authors: gillatt da. Cancers (Basel). 2020 Apr 16;12(4):984. doi: 10.3390/cancers12040984. Cancers (Basel). 2020. PMID: 32316186 Free PMC article.

3

Glypican-1 as a target for fluorescence molecular imaging of bladder cancer.

Polikarpov DM, Campbell DH, Zaslavsky AB, Lund ME, Wu A, Lu Y, Palapattu GS, Walsh BJ, Zvyagin AV, Gillatt DA. Polikarpov DM, et al. Among authors: gillatt da. Int J Urol. 2021 Dec;28(12):1290-1297. doi: 10.1111/iju.14683. Epub 2021 Sep 8. Int J Urol. 2021. PMID: 34498294

4

Safety and tolerability of Miltuximab^® - a first in human study in patients with advanced solid cancers.

Sabanathan D, Campbell DH, Velonas VM, Wissmueller S, Mazure H, Trifunovic M, Poursoltan P, Ho Shon K, Mackay TR, Lund ME, Lu Y, Roach PJ, Bailey DL, Walsh BJ, Gillatt D, Gurney H. Sabanathan D, et al. Asia Ocean J Nucl Med Biol. 2021 Spring;9(2):86-100. doi: 10.22038/AOJNMB.2021.55600.1386. Asia Ocean J Nucl Med Biol. 2021. PMID: 34250138 Free PMC article.

5

Functionalized Upconversion Nanoparticles for Targeted Labelling of Bladder Cancer Cells.

Polikarpov D, Liang L, Care A, Sunna A, Campbell D, Walsh B, Balalaeva I, Zvyagin A, Gillatt D, Guryev E. Polikarpov D, et al. Biomolecules. 2019 Dec 3;9(12):820. doi: 10.3390/biom9120820. Biomolecules. 2019. PMID: 31816991 Free PMC article.

6

Rapid and Label-Free Isolation of Tumour Cells from the Urine of Patients with Localised Prostate Cancer Using Inertial Microfluidics.

Rzhevskiy AS, Razavi Bazaz S, Ding L, Kapitannikova A, Sayyadi N, Campbell D, Walsh B, Gillatt D, Ebrahimi Warkiani M, Zvyagin AV. Rzhevskiy AS, et al. Cancers (Basel). 2019 Dec 29;12(1):81. doi: 10.3390/cancers12010081. Cancers (Basel). 2019. PMID: 31905736 Free PMC article.

7

Computer-assisted cystoscopy diagnosis of bladder cancer.

Gosnell ME, Polikarpov DM, Goldys EM, Zvyagin AV, Gillatt DA. Gosnell ME, et al. Among authors: gillatt da. Urol Oncol. 2018 Jan;36(1):8.e9-8.e15. doi: 10.1016/j.urolonc.2017.08.026. Epub 2017 Sep 25. Urol Oncol. 2018. PMID: 28958822

8

Development and evaluation of the MiCheck test for aggressive prostate cancer.

Shore ND, Pieczonka CM, Henderson RJ, Bailen JL, Saltzstein DR, Concepcion RS, Beebe-Dimmer JL, Ruterbusch JJ, Levin RA, Wissmueller S, Le TH, Gillatt D, Chan DW, Campbell DH, Walsh BJ. Shore ND, et al. Urol Oncol. 2020 Aug;38(8):683.e11-683.e18. doi: 10.1016/j.urolonc.2020.03.010. Epub 2020 Apr 16. Urol Oncol. 2020. PMID: 32305266

9

Proteomics discovery of radioresistant cancer biomarkers for radiotherapy.

Chang L, Graham P, Hao J, Bucci J, Malouf D, Gillatt D, Li Y. Chang L, et al. Cancer Lett. 2015 Dec 28;369(2):289-97. doi: 10.1016/j.canlet.2015.09.013. Epub 2015 Sep 30. Cancer Lett. 2015. PMID: 26427840 Review.

10

Communicating risk in active surveillance of localised prostate cancer: a protocol for a qualitative study.

Rapport F, Hogden A, Gurney H, Gillatt D, Bierbaum M, Shih P, Churruca K. Rapport F, et al. BMJ Open. 2017 Oct 5;7(10):e017372. doi: 10.1136/bmjopen-2017-017372. BMJ Open. 2017. PMID: 28982830 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

190 results

Search Page